HONG KONG, Dec. 2, 2010 /PRNewswire/ — OrbusNeich’s Genous
Stent shows favorable outcomes compared to bare metal stents (BMS)
for the treatment of coronary artery bifurcation lesions, according
to data published online in the journal
Atherosclerosis.
The cumulative rate of the study’s primary endpoint, the
composite of cardiac death, myocardial infarction (MI) or target
lesion revascularization (TLR) at one year follow-up, was 12.4% in
patients treated with a Genous Stent, a 30% reduction compared to
17.2% for the control group treated with BMS. The definite or
probable stent thrombosis (ST) rate was 1.7% for the Genous Stent
patient group, compared to 3.4% for the BMS treated patient
group.
“Interventional cardiologists continue to be challenged by the
15 to 20% of all percutaneous coronary interventions that involve
coronary artery bifurcation lesions,” said Marcel Beijk, M.D., of
the Academic Medical Center in Amsterdam, the lead author of the
paper. “The results of this large study of provisional T-stenting
using the Genous Stent are extremely encouraging. The endothelial
progenitor cell capture stent provides an excellent alternative to
bare metal stents for the treatment of these challenging
lesions.”
The paper, titled “One-year clinical outcome after provisional
T-stenting for bifurcation lesions with the endothelial progenitor
cell capturing stent compared with the bare-metal stent,” is based
on a single-center, non-randomized study. The study involved 178
consecutive patients who underwent percutaneous coronary
intervention for a de novo bifurcation lesion treated with a
Genous Stent and 465 consecutive patients treated with BMS.
About Genous
Genous is OrbusNeich’s patented endothelial progenitor cell
(EPC) capture technology that promotes the accelerated natural
healing of the vessel wall after
‘/>”/>
